No CrossRef data available.
Article contents
In Reply to “Thyrotoxic Periodic Paralysis, β2-Adrenergic Bronchodilator, and Insulin—An Interesting Interplay”
Published online by Cambridge University Press: 04 March 2015
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Letters • Correspondance
- Information
- Copyright
- Copyright © Canadian Association of Emergency Physicians 2014
References
1.
Yeh, FC, Chiang, WF, Wang, CC, Lin, SH. Thyrotoxic periodic paralysis triggered by b2-adrenergic bronchodilators. CJEM
2013;15:1–5.Google Scholar
2.
Senthilkumaran, S, Nath Jena, N, Jayaraman, S, Thirumalaikolundusubramanian, P. Thyrotoxic periodic paralysis, β2-adrenergic bronchodilator, and insulin—an interesting interplay. CJEM
2014;16:343.Google Scholar
3.
St-Pierre, DH, Benso, A, Gramaglia, E, et al. The metabolic response to the activation of the beta-adrenergic receptor by salbutamol is amplified by acylated ghrelin. J Endocrinol Invest
2010;33:363–7.Google Scholar
4.
Chang, CC, Cheng, CJ, Sung, CC, et al. A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants. Eur J Endocrinol
2013;169:529–36, doi:10.1530/EJE-13-0381.Google Scholar
5.
Jongjaroenprasert, W, Phusantisampan, T, Mahasirimongkol, S, et al. A genomewide association study identifies novel susceptibility genetic variation for thyrotoxic hypokalemic periodic paralysis. J Hum Genet
2012;57:301–4, doi:10.1038/jhg.2012.20.Google Scholar
6.
Ryan, DP, da Silva, MR, Soong, TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemicperiodic paralysis. Cell
2010; 140:88–98, doi:10.1016/j.cell.2009.12.024.CrossRefGoogle ScholarPubMed
You have
Access